HORMONE RESEARCH IN PÆDIATRICS

From Developmental Endocrinology to Clinical Research

Carotid IMT is fueled by androgens in CAH

(see paper by Kim et al., pp. 242–249)
Revolutionary changes in medical imaging have enormously improved the ability to detect structural and functional organ alterations early. Imaging is becoming an essential tool – in association with hormonal assays – for the diagnosis and management of endocrine disorders. New contrast media and their application to ultrasounds, as well as the opportunity to merge images acquired by functional/metabolic and traditional techniques, allow characterization of key features of identified lesions. Some radiological techniques such as ultrasonography, CT, and MRI are now available in operating rooms, thus supporting a diagnostic and therapeutic approach to endocrine diseases.

In this new book, distinguished experts have contributed concise and well-illustrated chapters to describe pathognomonic features of several benign and malignant diseases affecting endocrine glands. They review the main advantages and disadvantages of each diagnostic technique along with indications for selecting a method. As a special feature, online videos of dynamic diagnostic and therapeutic procedures are available.

*Imaging in Endocrine Disorders* is a must read and valuable reference for all professionals dealing with endocrine disorders, including internists and general practitioners who must manage the essential diagnostic workup.
HORMONE RESEARCH IN PÆDIATRICS

From Developmental Endocrinology to Clinical Research

Founded 1970 as 'Hormones' by M. Marois
Continued by J. Girard (1976–1995); M.B. Ranke (1996–2003);
P. Czernichow (2004–2013)

Editor-in-Chief
S. Cianfarani, Rome

Associate Editors
S.F. Ahmed, Glasgow
A. Belgorosky, Buenos Aires
M.T. Dattani, London
L.A. DiMeglio, Indianapolis, Ind.
M.W. Haymond, Houston, Tex.
O. Hiort, Lübeck
L. Ibáñez, Barcelona
E.A. Imel, Indianapolis, Ind.
P.-E. Mullis, Bern
S.E. Oberfield, New York, N.Y.
M. Phillip, Petah Tikva
M. Polak, Paris
O. Söder, Stockholm
R.J. Voutilainen, Kuopio
J.M. Wit, Leiden
J.I. Wolfsdorf, Boston, Mass.

Editorial Board
I.J.P. Arnhold, São Paulo
A. Bereket, Istanbul
J.-P. Bourguignon, Liège
J.-C. Carrel, Paris
F. Cassorla, Santiago
J.-P. Chanoine, Vancouver, B.C.
P.T. Cheung, Pokfulam
F. Chiarelli, Chieti
P.E. Clayton, Manchester
E. Codner, Santiago
E. Connor, Madison, Wis.
W. Cutfield, Auckland
C. Deal, Montreal, Que.
M. Donaldson, Glasgow
D.B. Dunger, Cambridge
L. Dunkel, London
U. Feldt-Rasmussen, Copenhagen
M. Freemark, Durham, N.C.
C. Gong, Beijing

J.J. Heinrich, Buenos Aires
A.C. Hokken-Koelega, Rotterdam
R. Horikawa, Tokyo
A. Hübsner, Dresden
K.Y. Loke, Singapore
C. Maffeis, Verona
C.J. Migeon, Baltimore, Md.
M. Misra, Boston, Mass.
M.B. Ranke, Tübingen
M.A. Rivarola, Buenos Aires
S.A. Rivkees, Gainesville, Fla.
R.G. Rosenfeld, Los Altos, Calif.
P. Saenger, New York, N.Y.
M.O. Savage, London
P.W. Speiser, Lake Success, N.Y.
T. Tanaka, Tokyo
G. Van Vliet, Montreal, Que.
R. Verkauskiene, Kaunas

(Continued on next page)
(Continued)

**ESPE Council 2016**

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secretary General</td>
<td>P. Clayton</td>
<td>Manchester</td>
</tr>
<tr>
<td>President</td>
<td>J.-C. Carel</td>
<td>Paris</td>
</tr>
<tr>
<td>Chair of Strategic and Finance Committee</td>
<td>A.C. Hokken-Koelega</td>
<td>Rotterdam</td>
</tr>
<tr>
<td>Chair of Clinical Practice Committee</td>
<td>G. Butler</td>
<td>London</td>
</tr>
<tr>
<td>Chair of Corporate Liaison Board</td>
<td>A. Grüters-Kieslich</td>
<td>Berlin</td>
</tr>
<tr>
<td>Chair of Education and Training Committee</td>
<td>J. Lebl</td>
<td>Prague</td>
</tr>
<tr>
<td>Chair of Programme Organising Committee</td>
<td>M. Dattani</td>
<td>London</td>
</tr>
<tr>
<td>Chair of the Scientific Committee</td>
<td>S.F. Ahmed</td>
<td>Glasgow</td>
</tr>
<tr>
<td>Chair of Communications Committee</td>
<td>G. Chrousos</td>
<td>Athens</td>
</tr>
</tbody>
</table>

**PES Board of Directors**

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>S. Radovick</td>
<td>New Brunswick, N.J.</td>
</tr>
<tr>
<td>President-Elect</td>
<td>S. Rosenthal</td>
<td>San Francisco, Calif.</td>
</tr>
<tr>
<td>Secretary</td>
<td>J.S. Fuqua</td>
<td>Indianapolis, Ind.</td>
</tr>
<tr>
<td>Treasurer</td>
<td>K. Rubin</td>
<td>Hartford, Conn.</td>
</tr>
<tr>
<td>Past President</td>
<td>M. Geffner</td>
<td>Los Angeles, Calif.</td>
</tr>
<tr>
<td>At Large Directors</td>
<td>C. Alter</td>
<td>Philadelphia, Pa.</td>
</tr>
<tr>
<td></td>
<td>B.A. Boston</td>
<td>Portland, Oreg.</td>
</tr>
<tr>
<td></td>
<td>D. Shulman</td>
<td>Tampa, Fla.</td>
</tr>
</tbody>
</table>
Hormone Research in Paediatrics

Aim and Scope

Hormone Research in Paediatrics aims to provide rapid publication of clinical investigations, mini reviews and novel insights from clinical experience, as well as experimental and methodological work related to paediatric and adolescent endocrinology. Correspondence is welcome, but publication of letters is at the discretion of the editors.

Submission

Manuscripts written in English should be submitted using the online submission website at:

www.karger.com/hrp

Should you have any problems with your submission, please contact the Editorial Office:

hrp@karger.com

Prof. S. Cianfarani
S. Karger AG
Editorial Office 'Hormone Research in Paediatrics'
P.O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1437
Fax +41 61 306 1434

They should be accompanied by a signed copyright transfer statement (please see submission website). The names and addresses of four experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s).

Main Sections

1. Original papers

Any original papers on hormone research are accepted; we particularly welcome papers on developmental and clinical research.

2. Mini reviews

Most mini reviews are submitted upon invitation. However, the editors are open to unsolicited mini reviews. Authors planning such a mini review are requested to contact the Editorial Office with an outline of the intended mini review. All mini reviews are subject to peer review. The guidelines for the mini reviews can be found at www.karger.com/hrp_guidelines#11.

3. Novel insights from clinical practice

We invite contributions to this section that provide novel insight into a clinical problem. We recognise the value of case reports and thus submissions can be based around a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognised clinical scenario or may represent an entirely new clinical condition. The novel aspects of the case(s) may be in the phenotype, the presentation, the investigation and/or the management. Manuscripts revealing novel mechanisms are of particular interest. Papers repeating known phenotypes or mutations in a novel context are not acceptable.

We propose that a highlighted box containing one or two bullet points on ‘Established facts’ and ‘Novel insights’ be placed on the first page of the report. This reinforces the novelty of the clinical observation. The manuscript should be presented with an abstract (up to 200 words), brief introduction, case or case series description and results, followed by a discussion. No limits on length or number of references are imposed. Statements for the highlighted box should also be included.

Conditions

All manuscripts are subject to editorial review. The names and addresses of six experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s). Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Hormone Research in Paediatrics and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 200 words. It should be structured as follows:

Background/Aims: What is the major problem that prompted the study?

Methods: How was the study done?

Results: Most important findings?

Conclusion: Most important conclusion?

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 x 223 mm) or provide crop marks.

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surname of the authors followed by initials should be given.

There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastectomy patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their own web-site or on an institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

Guidelines for Authors

Hormone Research in Paediatrics

© 2016 S. Karger AG, Basel

KARGER

E-Mail karger@karger.com

The Guidelines for Authors are available at:

www.karger.com/hrp_Guidelines

Downloaded by: 54.191.40.80 - 9/17/2017 9:32:17 AM
HORMONE RESEARCH IN PÄDIATRICS

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com
• Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author's behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's Choice™ (Gold Open Access) articles, see Author's Choice™.

Author's Choice™
Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:
• Follow the terms of the relevant Creative Commons license
• Be linked to the final version on www.karger.com
• Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges
There is no page charge for papers of 4 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 650.00. The allotted size of a paper is equal to approx. 12 manuscript pages (including tables, illustrations and references). As the page charges are waived in any case for the first paper each year to be published by a member of ESPE or PES, authors who are members of the ESPE or PES should so indicate on the title page.

Proofs
Unless indicated otherwise, a PDF for correction is sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

E-pub First
All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors’ approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints
Order form and price list is sent with the PDF. Orders submitted after the issue is printed are subject to considerably higher prices.
This special issue of *Neuroendocrinology* brings together a series of new aspects in GnRH research, encompassing fundamental studies on the regulation of the GnRH neuron at a molecular and electrophysiological level, studies on pulsatile gene expression in GnRH-promoter-luciferase transgenic mice, and the impact of novel guidance proteins (semaphorins) on GnRH neuron migration. Further topics include animal models of metabolic, immunological, bacterial and steroidogenic reproductive neuroendocrine programming, and clinical studies on the use of kisspeptin ligands to stimulate or inhibit the reproductive system. The discoveries and proposals made in this issue promise to revolutionize the current understanding of the mechanism of GnRH neuron regulation of reproduction, and will be essential reading for anyone involved in the field of GnRH research.

**Contents**

**Preface**
- New Insights into GnRH Neuron Development, Programming and Regulation in Health and Disease: Millar, R.P.

**At the Cutting Edge**
- Kisspeptin and Gonadotropin-Releasing Hormone Neuronal Excitability: Molecular Mechanisms Driven by 17ß-Estradiol: Ronneklev, O.K.; Zhang, C.; Bosch, M.A.; Kelly, M.J.
- Shaping the Reproductive System: Role of Semaphorins in Gonadotropin-Releasing Hormone Development and Function: Giacobini P.
- Factors in Early-Life Programming of Reproductive Fitness: Sominsky, L.; Fuller, E.A.; Hodgson, D.M.
- Steroidogenic versus Metabolic Programming of Reproductive Neuroendocrine, Ovarian and Metabolic Dysfunctions: Cardoso, R.C.; Puttabyatappa, M.; Padmanabh, V.
- Potential Clinical Use of Kisspeptin: Prague, J.K.; Dhillo, W.S.

Author Index/Subject Index
Contents

See the journal website for contents
JOIN OVER 1,000 PHYSICIANS AND INVESTIGATORS FROM AROUND THE world to share the newest clinical and basic science research on thyroid disease. The ATA Program Committee led by Co-Chairs Peter Arvan and Stephanie Fish will develop a scientific program to satisfy the interests of all audiences. The Ridgway Trainee Conference along with the full-day satellite ultrasound course and hands-on practicum will be available again to accent the main scientific program. Experience top-notch educational sessions, great networking and mentoring opportunities along with unmatched collegiality.

ATA 2016 CALL FOR ABSTRACT SUBMISSIONS

Regular Call:
Site Open Now
Site Closes – Wednesday, May 25, 2016

Short Call:
Site Opens – Wednesday, July 27, 2016
Site Closes – Wednesday, August 10, 2016

REGISTRATION and HOUSING OPENING IN SPRING 2016
Agenda and meeting updates will be posted as available. Exhibitor and sponsor opportunities available as well.

® Not an ATA Member?
It’s always a good time to join. Sign up at www.thyroid.org. Please join the ATA for its many benefits, including reduced meeting registration and many ways to participate in the thyroid field. ATA members are eager to welcome you to this extraordinary society.

6066 Leesburg Pike, Suite 550, Falls Church VA 22041 USA
703.998.8890 thyroid@thyroid.org www.thyroid.org
SAVE THE DATE

10-12 SEPTEMBER, PARIS, FRANCE

55th Annual ESPE Meeting
Horizons in Paediatric Endocrinology

Abstract submission deadline:
11 April 2016
Early bird deadline:
10 June 2016
Standard registration deadline
25 July 2016
JOIN US!

ISPAD 2016

October 26 – 29, 2016 | VALENCIA, SPAIN

Education and New Technologies: Enhancing Care in Diabetes

2016.ispad.org
www.ispad.org
The European Thyroid Journal publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.

European Thyroid Journal
Official Journal of the European Thyroid Association

Editor-in-Chief
W.M. Wiersinga,
Amsterdam

Associate Editors
J. Koehrle, Berlin
(Basic Thyroidology)
P. Laurberg, Aalborg
(Clinical Thyroidology)
F. Pacini, Stena
(Thyroid Cancer)
L. Persani, Milan
(Translational Thyroidology)

Selected contributions
• Bioassays for TSH Receptor Antibodies: Quo Vadis? Kahaly, G.J. (Mainz)
• DuOx2 Promoter Regulation by Hormones, Transcriptional Factors and the Coactivator TA2: Cardoso-Weide, L.C. (Niterói); Cardoso-Penha, R.C. (Rio de Janeiro); Costa, M.W. (Melbourne, Vic.); Ferreira, A.C.F.; Carvalho, D.P. (Rio de Janeiro); Santisteban, P.S. (Madrid)
• Iodine, Thyroid Autoimmunity and Cancer: Fiore, E.; Latrofa, F.; Vitti, P. (Pisa)
• Clinical Consequences of Mutations in Thyroid Hormone Receptor-α1: van Mullem, A.A.; Visser, T.J.; Peeters, R.P. (Rotterdam)
• Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels: Debeij, J.; Cannegieter, S.C. (Leiden); van Zaane, B.; van Zanten, A.P. (Amsterdam); Rosendaal, F.R. (Leiden); Gerdes, V.E.A. (Amsterdam); Reitsma, P.H.; Dekkers, O.M. (Leiden)
• 2014 European Thyroid Association Guidelines for the Management of Subclinical Hypothyroidism in Pregnancy and in Children: Lazarus, J. (Cardiff); Brown, R.S. (Boston, Mass.); Daumerie, C. (Brussels); Hubalewska-Dydejczyk, A. (Krakow); Negro, R. (Lecce); Vaidya, B. (Exeter)
• A Progress Report of the IFCC Committee for Standardization of Thyroid Function Tests: Thiennpont, L.M.; Van Uytvanque, K.; Van Houcke, S. (Ghent); Das, B. (Mumbai); Faix, J.D.; (Palo Alto, Calif.); MacKenzie, F. (Birmingham); Quinn, F.A. (Abbott Park, Ill.); Rottmann, M. (Penzberg); Van den Brule, A. (Bruges) for the IFCC Committee for Standardization of Thyroid Function Tests (C-STFT)
• Structure and Function of Thyroid Hormone Plasma Membrane Transporters: Schweizer, U. (Bonn); Johannes, J. (Berlin); Bayer, D.; Braun, D. (Bonn)

More information at www.karger.com/etj
Mini Review

221 Glucocorticoid Programming in Very Preterm Birth
Finken, M.J.J.; van der Voorn, B.; Heijboer, A.C.; de Waard, M.; van Goudoever, J.B.; Rotteveel, J. (Amsterdam)

Original Papers

232 Fibroblast Growth Factor 23 Concentrations Reflect Sex Differences in Mineral Metabolism and Growth in Early Infancy
Holmlund-Suila, E.; Viljakainen, H. (Helsinki); Ljunggren, O. (Uppsala); Hytinantti, T.; Andersson, S. (Helsinki); Mäkitie, O. (Helsinki/Stockholm)

242 Carotid Intima-Media Thickness Is Associated with Increased Androgens in Adolescents and Young Adults with Classical Congenital Adrenal Hyperplasia
Kim, M.S.; Dao-Tran, A.; Davidowitz, E.; Tseng, T.; Gilsanz, V.; Ryabets-Lienhard, A.; Nguyen, E.; Geffner, M.E. (Los Angeles, Calif.)

250 Impaired Hemorheological Parameters and Increased Carotid Intima-Media Thickness in Children with Subclinical Hypothyroidism

257 Influence of Antenatal Glucocorticosteroid Exposure on Osteoprotegerin and Receptor Activator of Nuclear Factor kB Ligand Levels in Newborn Infants

265 Adding Glucagon-Stimulated GH Testing to the Diagnostic Fast Increases the Detection of GH-Sufficient Children

Controversial Issues

273 The 2015 Pediatric Endocrine Society Ethics Symposium: Controversies Regarding ‘Gender Verification’ of Elite Female Athletes – Sex Testing to Hyperandrogenism
Brodsky, J.L. (Poughkeepsie, N.Y.); Genel, M. (New Haven, Conn.)

278 Hormonal Eligibility Criteria for ‘Includes Females’ Competition: A Practical but Problematic Solution
Allen, D.B. (Madison, Wis.)

Novel Insights from Clinical Practice

283 Early-Onset Central Diabetes Insipidus due to Compound Heterozygosity for AVP Mutations
Bourdet, K.; Vallette, S.; Deladoï, J.; Van Vliet, G. (Montreal, Que.)

288 Expanding the CHARGE Geno-Phenotype: A Girl with Novel CHD7 Deletion, Hypogonadotropic Hypogonadism, and Agenesis of Uterus and Ovaries
Reynaert, N.; de Zegher, F.; Francois, I.; Devriendt, K.; Beckers, D.; Casteels, K. (Leuven)